VEGF-targeted therapy: mechanisms of anti-tumour activity
Top Cited Papers
- 3 July 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 8 (8), 579-591
- https://doi.org/10.1038/nrc2403
Abstract
No abstract availableKeywords
This publication has 101 references indexed in Scilit:
- Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growthProceedings of the National Academy of Sciences of the United States of America, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerThe New England Journal of Medicine, 2007
- Non-Uniform Plasma Leakage Affects Local Hematocrit and Blood Flow: Implications for Inflammation and Tumor PerfusionAnnals of Biomedical Engineering, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Therapeutic stem and progenitor cell transplantation for organ vascularization and regenerationNature Medicine, 2003
- VEGF165 mediates formation of complexes containing VEGFR‐2 and neuropilin‐1 that enhance VEGF165‐receptor bindingJournal of Cellular Biochemistry, 2002
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971